PTGS2 and familial dilated cardiomyopathy: DFO has been shown to ameliorate cardiomyocyte injury in an in vitro DCM model of ECT exposed to AGE, reducing the expression of the lipid peroxidation marker malondialdehyde (MDA) and the ferroptosis marker prostaglandin-endoperoxide synthase-2 (PTGS2), improving ECT cardiomyocyte function.